BEAM — Beam Therapeutics Inc
NASDAQ · Healthcare · Biotechnology
$29.02
-$0.41 (-1.39%)
Beam Therapeutics Inc (BEAM) is a biotechnology company listed on NASDAQ. It is led by John M. Evans M.B.A., based in 238 Main Street, Cambridge, MA, United States, 02142, with about 393 employees. Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease; BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. It also intends to develop BEAM-103, an anti-CD117 monoclonal antibody, and BEAM-104, a cell therapy for development in sickle cell disease and beta-thalassemia; and BEAM-201 and other potential ex vivo CAR-T therapies. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.
Latest reported BEAM revenue for 2025-09-30 was $9.7M. Net income was -$324.3M. Revenue was up 14.6% from 2025-06-30 to 2025-09-30. BEAM currently screens at market cap $2.01B.
Use this BEAM page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the BEAM quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the BEAM SEC filings page. Lician reads the product cache first so this HTML stays unique to Beam Therapeutics Inc even when a live quote feed is slow.
About Beam Therapeutics Inc
Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease; BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. It also intends to develop BEAM-103, an anti-CD117 monoclonal antibody, and BEAM-104, a cell therapy for development in sickle cell disease and beta-thalassemia; and BEAM-201 and other potential ex vivo CAR-T therapies. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.
BEAM Key Statistics
Market Cap
$2.01B
Volume
636,268
Previous Close
$28.33
Day Range
$28.78 – $31.23
EPS
-$4.58
Revenue
$63.52M
Net Income
-$376.74M
Gross Profit
$0.00
Free Cash Flow
$0.00
Revenue Growth
-83.2%
Profit Margin
-593.1%
Employees
393
BEAM Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $63.52M | $377.71M | $60.92M | $51.84M |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$376.74M | -$132.53M | -$289.09M | -$370.64M |
| EPS (Diluted) | -$4.58 | -$1.72 | -$4.13 | -$5.77 |
Total Assets
$1.10B
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$281.97M
Operating Cash Flow
-$347.25M
Free Cash Flow
$0.00
Beam Therapeutics Inc Company Information
- CEO & Director
- John M. Evans M.B.A.
- Headquarters
- 238 Main Street, Cambridge, MA, United States, 02142
- Website
- beamtx.com
- Phone
- 857 327 8775
- IPO / Founded
- 2020-02-06
- Sector
- Healthcare
- Industry
- Biotechnology